LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

LivaNova (NASDAQ:LIVN) had its price objective increased by equities research analysts at Stifel Nicolaus from $65.00 to $70.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 7.78% from the stock’s current price.

A number of other research firms have also weighed in on LIVN. Weiss Ratings reissued a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Mizuho upped their target price on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $75.00 price target on LivaNova in a report on Tuesday, December 16th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, KeyCorp started coverage on shares of LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and an average price target of $66.88.

LivaNova Trading Up 0.5%

Shares of LIVN opened at $64.95 on Wednesday. The company’s fifty day simple moving average is $59.87 and its 200-day simple moving average is $53.89. The company has a market cap of $3.55 billion, a P/E ratio of -16.24 and a beta of 0.97. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. LivaNova has a twelve month low of $32.48 and a twelve month high of $65.57.

Institutional Trading of LivaNova

A number of hedge funds have recently bought and sold shares of LIVN. Amundi boosted its holdings in LivaNova by 7.2% in the first quarter. Amundi now owns 196,435 shares of the company’s stock worth $7,362,000 after acquiring an additional 13,142 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of LivaNova by 79.6% during the second quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after acquiring an additional 38,451 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of LivaNova by 20.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company’s stock valued at $4,599,000 after purchasing an additional 17,252 shares during the last quarter. Aberdeen Group plc raised its position in shares of LivaNova by 18.1% in the 2nd quarter. Aberdeen Group plc now owns 326,786 shares of the company’s stock valued at $14,712,000 after purchasing an additional 50,076 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in LivaNova in the 2nd quarter worth approximately $1,713,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.